Genocea Biosciences (GNCA) Reaches New 1-Year Low at $0.81

Genocea Biosciences Inc (NASDAQ:GNCA)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $0.81 and last traded at $1.08, with a volume of 998600 shares trading hands. The stock had previously closed at $1.13.

Several equities analysts have weighed in on the stock. ValuEngine downgraded shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 26th. Cowen restated a “buy” rating and set a $10.00 target price on shares of Genocea Biosciences in a report on Tuesday, September 26th. Needham & Company LLC downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Zacks Investment Research downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Stifel Nicolaus downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $15.00 to $2.50 in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $6.25.

The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51. The company has a market cap of $23.99, a price-to-earnings ratio of -0.50 and a beta of 1.94.

Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same quarter in the previous year, the firm posted ($0.45) EPS. equities analysts predict that Genocea Biosciences Inc will post -1.91 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in GNCA. Schwab Charles Investment Management Inc. acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth about $257,000. Rhumbline Advisers acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth about $157,000. Bank of New York Mellon Corp boosted its stake in shares of Genocea Biosciences by 594.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 72,008 shares during the last quarter. Teachers Advisors LLC acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth about $268,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth about $404,000. 34.69% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Genocea Biosciences (GNCA) Reaches New 1-Year Low at $0.81” was first published by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://baseballnewssource.com/markets/genocea-biosciences-gnca-reaches-new-1-year-low-at-0-81/1842720.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.